Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity
15/07/2025 13:25
July 15 (Reuters) - Palatin Technologies Inc PTNT.PK: PALATIN ANNOUNCES POSITIVE PRECLINICAL EFFICACY DATA FOR ORAL MC4R AGONIST PL7737 IN ANIMAL MODEL OF OBESITY PALATIN TECHNOLOGIES INC - PL7737 AND TIRZEPATIDE SHOW ADDITIVE WEIGHT LOSS EFFECTS PALATIN TECHNOLOGIES INC - ORAL PL7737 SHOWS RAPID WEIGHT LOSS AFTER 4 DAYS PALATIN TECHNOLOGIES INC - IND SUBMISSION FOR PL7737 PLANNED FOR 4Q2025 Source text: ID:nPn19d2dFa Further company coverage: PTNT.PK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palatin Technologies
See all newsPalatin Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity